Ropes & Gray represented Teva Pharmaceuticals International GmbH in a strategic global licensing agreement with mAbxience for a biosimilar candidate currently in development for the treatment of multiple oncology indications. The transaction was announced on April 4. Financial terms were not disclosed.
Under the licensing agreement, mAbxience will leverage its experience in biosimilar development to develop and produce the biosimilar product. Teva will lead the regulatory process and commercialization in the designated regions, to ensure access to a broader patient population.
The Ropes & Gray team was led by life sciences licensing partner Abigail Gregor and life sciences licensing associate Evan Tallmadge.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.